Volver a Agenda
Session Chair(s)
Ginny Beakes-Read, BSN, JD
VP, Global Regulatory Policy
Johnson & Johnson Innovative Medicine, United States
Learning Objective : Identify issues associated with Drug Enforcement Agency (DEA) scheduling of new drugs with abuse potential; Describe possible approaches to allow for timely DEA scheduling of drugs so that they may be marketed and available for patients upon FDA approval.
Speaker(s)
Framework for Pharmaceutical product Scheduling Under the Controlled Substances Act
Lynn W. Mehler, JD
HoganLovells, United States
Partner
A Former Regulators Perspective on Controlled Substance Scheduling
Alan G. Santos
Pyramid Healthcare Solutions, United States
Vice President, Pharmaceutical Compliance and Related Services
The Science of Abuse Liability Assessment: History and Future Challenges
Lawrence Carter, PHD
Jazz Pharmaceuticals, United States
Director, Clinical Development
¿Tiene una cuenta?